Vyome Biosciences raises $14 million in Series-C funding

Vyome Biosciences, a clinical-stage speciality bio-pharmaceutical company developing novel medicines for treating skin diseases caused by resistant microbes announced in Monday that it has closed $14 million Series-C financing round. This financing round was led by Perceptive Advisors, a leading New York based life sciences fund and, Romulus Capital, a Boston-based venture capital firm, along with participation from existing investors including Kalaari Capital, Sabre Partners and Aarin Capital.

Vyome is an innovation driven clinical stage bio-pharmaceutical company, which has a pipeline of novel drugs for antibiotic resistant acne, other opportunistic pathogens and antifungal agents in dermatology. Vyome's lead